Relapsed Or Refractory B Cell Malignancies

1

Review clinical trials related to Relapsed Or Refractory B Cell Malignancies. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

Participants needed: 85
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Updated: Jun 11, 2026Locations: 9
Eligibility criteria

Age ≥18 years at the time of signing the informed consent. [+3]

Any medical or psychiatric condition that, in the view of the Principal Investig... [+3]